<DOC>
	<DOCNO>NCT00962832</DOCNO>
	<brief_summary>This Phase II , randomize , double-blind , placebo-controlled multicenter study evaluate efficacy safety rontalizumab compare placebo patient moderately severely active systemic lupus erythematosus ( SLE ) .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Rontalizumab Patients With Moderately Severely Active Systemic Lupus Erythematosus</brief_title>
	<detailed_description>The study conduct 3 part . Parts 1 2 study include double-blind treatment period 24 week safety follow-up period 48 week participant continue onto Part 3 . Patients meet eligibility criterion enrollment Part 3 , enter Part 3 completion Week 24 visit prior completion Week 72 visit . In Part 1 , participant randomize 2:1 ratio ( active drug : placebo ) receive either rontalizumab 750 mg match placebo intravenously every 4 week 24 week . Part 2 initiated upon completion recruitment Part 1 . In Part 2 , participant randomize 2:1 ratio ( active drug : placebo ) receive either rontalizumab 300 mg match placebo subcutaneously every 2 week 24 week . After Week 24 , patient enter 48-week safety follow-up period , , open label extension become available via protocol amendment , option enter Part 3 study , eligible . In Part 3 , participant receive rontalizumab 750 mg intravenously every 4 week 120 week ( 144 week total ) .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Diagnosis SLE . Active disease time screen . Agreement use effective form contraception duration study . Acutely life organthreatening manifestation systemic lupus erythematosus ( SLE ) ( eg , proliferative nephritis , unstable neuropsychiatric disease ) . Pregnancy breastfeed . History severe allergic anaphylactic reaction monoclonal antibody intravenous ( IV ) immunoglobulin . Significant , uncontrolled medical disease organ system related SLE investigator 's opinion would preclude patient participation . Concomitant condition require systemic corticosteroid use within 1 year prior screen . Use topical , intraarticular , inhaled corticosteroid exclusionary . History cancer within 5 year screen . Any current recent ( within 4 week screen ) sign symptoms infection , except minor infection , fungal infection nail bed , oral vaginal candidiasis . History severe systemic bacterial , fungal , viral , parasitic infection ( 2 hospitalization 2 course IV antibiotic ) within 6 month prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>rhuMAb IFNalpha</keyword>
	<keyword>SLE</keyword>
</DOC>